Chi Sheng Pharma & Biotech Co (ROCO:4111) ROCE %: 15.98% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4111 Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
84 GF Score
Price NT$30.05
GF Value NT$33.14
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chi Sheng Pharma & Biotech Co ROCE %?

Chi Sheng Pharma & Biotech Co ROCO:4111 -0.66% 84 ROCE % is 15.98% as of Dec. 2025. GuruFocus rates ROCO:4111 with a GF Score™ of 84/100 and a GF Value™ of NT$33.14 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chi Sheng Pharma & Biotech Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 15.98%.

Chi Sheng Pharma & Biotech Co  (ROCO:4111) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chi Sheng Pharma & Biotech Co ROCE % Related Terms

Chi Sheng Pharma & Biotech Co ROCE % Historical Data

* Premium members only.

The historical data trend for Chi Sheng Pharma & Biotech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chi Sheng Pharma & Biotech Co ROCE % Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.04 12.94 6.74 10.36 14.53

Chi Sheng Pharma & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.41 14.14 12.49 16.07 15.98
ROCO:4111
84GF Score
Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chi Sheng Pharma & Biotech Co ROCE % Calculation

Chi Sheng Pharma & Biotech Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=207.32/( ( (1749.63 - 372.801) + (1937.777 - 461.001) )/ 2 )
=207.32/( (1376.829+1476.776)/ 2 )
=207.32/1426.8025
=14.53 %

Chi Sheng Pharma & Biotech Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=232.244/( ( (1906.082 - 477.052) + (1937.777 - 461.001) )/ 2 )
=232.244/( ( 1429.03 + 1476.776 )/ 2 )
=232.244/1452.903
=15.98 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.98% mean?
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a ROCE % of 15.98% as of Dec. 2025.
Is Chi Sheng Pharma & Biotech Co's ROCE % too high?
Chi Sheng Pharma & Biotech Co's current ROCE % is 15.98%. The Medical Devices & Instruments industry median ROCE % is 2.26. Chi Sheng Pharma & Biotech Co's value of 15.98% is 607.1% above this industry median. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's ROCE % compare to ISRG and BDX?
Chi Sheng Pharma & Biotech Co's ROCE % of 15.98% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.26. Chi Sheng Pharma & Biotech Co's value of 15.98% is 607.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.26, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current ROCE % of 15.98% is 607.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current ROCE % is 15.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$30.05 — trading 9.3% below its estimated fair value. The current ROCE % is 15.98% and 607.1% above the Medical Devices & Instruments industry median of 2.26. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current ROCE % is 15.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?

Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued. The current stock price of NT$30.05 is trading 9.3% below its estimated GF Value™ of NT$33.14. GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.

Key valuation signals for ROCO:4111:

  • ROCE %: 15.98%
  • GF Value™: NT$33.14 vs. price of NT$30.05 (9.3% below fair value)
  • GF Score™: 84/100 with 1 warning sign
  • Industry Position: 607.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chi Sheng Pharma & Biotech Co Business Description

Address No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score

Get the complete analysis for ROCO:4111

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.05
Price
NT$33.14
GF Value